Regeneron Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Regeneron Pharmaceuticals's estimated annual revenue is currently $13.4B per year.
- Regeneron Pharmaceuticals's estimated revenue per employee is $771,184
- Regeneron Pharmaceuticals's current valuation is $66.2B. (January 2022)
Employee Data
- Regeneron Pharmaceuticals has 17324 Employees.
- Regeneron Pharmaceuticals grew their employee count by 8% last year.
Regeneron Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Regeneron Pharmaceuticals?
Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammation. The Company also has preclinical programs in asthma, allergies, and other diseases and disorders. Regeneron has developed several proprietary platform technologies, which it has incorporated into a comprehensive discovery and development process designed to understand thoroughly the biology of specific disease states, discover potential therapeutic candidates, and evaluate these candidates in clinical trials.
keywords:N/A
N/A
Total Funding
17324
Number of Employees
$13.4B
Revenue (est)
8%
Employee Growth %
$66.2B
Valuation
N/A
Accelerator
Regeneron Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President, CEO and Board Co-Chair | Reveal Email/Phone |
2 | EVP & General Manager, Industrial Operations & Product Supply | Reveal Email/Phone |
3 | V.P., Regeneron Pharmaceuticals - Chief Business and Admin. Officer, Regeneron Genetics Center | Reveal Email/Phone |
4 | Senior Director, Workplace Strategy & Planning | Reveal Email/Phone |
5 | SVP, CMC Regulatory Sciences and Industrial Affai | Reveal Email/Phone |
6 | SVP Research and Development Sciences | Reveal Email/Phone |
7 | VP | Reveal Email/Phone |
8 | Director, Vendor & Relationship Management | Reveal Email/Phone |
9 | EVP, General Counsel and Secretary | Reveal Email/Phone |
10 | Associate Director, Technical Training Compliance | Reveal Email/Phone |
Regeneron Pharmaceuticals News
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of Buy from Brokerages. Posted by admin on Apr 19th, 2022.
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced Tuesday its agreement to acquire Checkmate Pharmaceuticals, Inc. (CMPI) at an...
TARRYTOWN, N.Y., Nov. 16, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Evercore ISI 4th Annual HealthCONx Conference at 9:15 a.m. ET on Tuesday, November 30, 2021 Piper Sandler 33rd Annual Healthcare Conference at 8:00 a.m. ...
TARRYTOWN, N.Y., Nov. 16, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Evercore ISI 4th Annual HealthCONx Conference at 9:15 a.m. ET on Tuesday, November 30, 2021 Piper Sandler 33rd Annual Healthcare Conference at 8:00 a.m. ...